Elahe Baghizadeh

Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial

G. Lip, G. Stone, S. Parikh, 2021 .

Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial

G. Lip, H. Krumholz, G. Stone, 2021, Thrombosis and Haemostasis.

Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial

G. Lip, G. Stone, S. Parikh, 2023, Thrombosis and Haemostasis.

Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial

B. Bikdeli, H. Bakhshandeh, H. Sezavar, 2022, BMJ.

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.

S. Parikh, B. V. Van Tassell, M. Monreal, 2021, JAMA.